PMCB vs PPCB

PharmaCyte Biotech, Inc. vs Propanc Biopharma, Inc. — Valuation Comparison 2026

PMCB

Biotechnology
PharmaCyte Biotech, Inc.
Quality
5.1
out of 10
Value Trap
12
SAFE
Price
$0.86
Last close
Models
4/13
Active
VS

PPCB

Biotechnology
Propanc Biopharma, Inc.
Quality
3.7
out of 10
Value Trap
36
LOW
Price
$1.70
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType PMCB Fair ValuePMCB Upside PPCB Fair ValuePPCB Upside
Bayesian DCF Intrinsic $0.50 -70.8%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $5.13 +498.5% $2.80 +60.3%
Dynamic NAV Asset-Based $2.46 +186.9% $6.64 +290.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PMCB vs PPCB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PMCB vs PPCB — Which Stock Is More Undervalued?

PMCB scores higher with a 5.1/10 quality rating vs PPCB's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing PharmaCyte Biotech, Inc. (PMCB) and Propanc Biopharma, Inc. (PPCB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PMCB currently trades at $0.86 with a QOC of 5.1/10, while PPCB trades at $1.70 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).